Saturday 17 October 2026 Export CTXR’s income statement to Excel — free account

Citius Pharmaceuticals, Inc.

In the quarter to June 2026, EPS grew 57.5% and free cash flow fell 60.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.46 0.00 0.00%

Follow CTXR

Alert me

Market cap: $12.6M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 12.63

Revenue —

Net Income (58.17)

Free Cash Flow (34.87)

Net Debt (10.60)

Current Ratio 0.84

Debt/Equity 0.08

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.16

Past 5Y EPS Growth —

This Y EPS Growth 39.94%

Next Y EPS Growth 29.06%

Next Y revenue growth —

Next 5Y EPS Growth 41.69%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 2.94%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	26	3	4	17
Receivables	—	—	—	1
Inventory	—	8	22	23
Other	—	—	—	—
	34	14	28	43

	2023	2024	2025	Q'26
Payables	3	5	14	8
ST’ Debt	—	—	—	—
Other	3	28	23	16
	6	36	45	52

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	18.15%	(9.16%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(13)	(1)	(9)	—	—
’25	(5)	(5)	(5)	(12)	(27)
’24	(6)	(8)	(8)	(6)	(28)
’23	(5)	(8)	(10)	(7)	(29)
’22	(5)	(10)	(8)	(6)	(28)
’21	(10)	(4)	(5)	(6)	(24)
’20	(5)	(4)	(4)	(3)	(17)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(13)	(1)	(9)	—	—
’25	(5)	(5)	(5)	(12)	(27)
’24	(6)	(8)	(8)	(6)	(28)
’23	(5)	(8)	(10)	(7)	(29)
’22	(5)	(10)	(8)	(6)	(28)
’21	(10)	(4)	(5)	(6)	(24)
’20	(5)	(4)	(4)	(3)	(17)

Fiscal quarters ending in the months shown.

EPS $

	Dec	Mar	Jun	Sep	Year
’26	(0.38)	(0.95)	(0.34)	—	—
’25	(1.30)	(1.27)	(0.80)	(0.04)	(3.38)
’24	(1.50)	(1.25)	(1.50)	(1.55)	(5.97)
’23	(0.50)	(1.75)	(1.50)	(1.75)	(5.50)
’22	(1.50)	(1.25)	(1.50)	(1.25)	(5.75)
’21	(3.75)	(1.00)	(1.25)	(0.75)	(5.75)
’20	(3.75)	(3.25)	(2.75)	(1.75)	(11.25)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	63.75	64.00	23.40	10.00	10.38	25.00	19.25	15.00	2.44	0.63	Analyst estimates 2026–2028 Powerpack
	High	937.50	365.63	115.00	44.75	49.25	114.00	50.25	42.75	26.75	4.51
People
People	Employees	6	7	7	9	10	15	21	22	23	23
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—
	EBT	(8)	(10)	(13)	(16)	(18)	(23)	(33)	(32)	(39)	(39)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(8)	(10)	(13)	(16)	(18)	(23)	(34)	(33)	(39)	(40)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(57.24)	(47.36)	(29.25)	(17.12)	(11.25)	(5.75)	(5.75)	(5.50)	(5.97)	(3.38)
	Cash flow	(40.72)	(36.35)	(26.36)	(15.42)	(10.81)	(5.58)	(4.85)	(4.80)	(4.19)	(2.40)
	Capex	0.00	(0.01)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(40.72)	(36.36)	(26.36)	(15.42)	(10.81)	(5.58)	(4.85)	(4.80)	(4.19)	(2.40)
	Book value	115.71	100.08	64.91	33.67	21.49	30.57	17.70	15.11	11.02	7.01
	Shares, m	0	0	0	1	2	4	6	6	7	11
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(6)	(8)	(11)	(12)	(17)	(24)	(28)	(29)	(28)	(27)
	Capex	—	0	—	—	0	0	—	—	—	—
	Free cash flow	(6)	(8)	(11)	(12)	(17)	(24)	(28)	(29)	(28)	(27)
Balance, $m
Balance, $m	Working capital	(4)	1	7	3	10	69	40	29	(22)	(17)
	Total debt	1	0	0	0	0	1	0	0	—	—
	Net debt	0	(3)	(9)	(8)	(14)	(70)	(42)	(26)	(3)	(4)
	Shareholders’ equity	17	22	28	27	34	133	103	91	74	78
Returns, %
Returns, %	ROA	(73.12)	(44.79)	(45.20)	(45.91)	(43.59)	(26.32)	(26.24)	(30.97)	(36.49)	(30.24)
	ROIC	(28.27)	(33.30)	(46.13)	(50.62)	(55.41)	(23.45)	(33.74)	(35.35)	(37.05)	(32.86)
	ROE	(102.85)	(53.65)	(50.33)	(56.57)	(57.70)	(29.44)	(28.48)	(34.58)	(48.55)	(49.38)

Negative figures in brackets.

All 10 years →

Latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ICU SeaStar Medical Holding Corporation	$13.5M	— (loss-making)	— (loss-making)	+81.95% (above 0%: growing)	n/m	+0.43% (above 0%: growing)	91.22%	(616.42%)	Compare
HIND Vyome Holdings, Inc.	$13.4M	0.0×	— (loss-making)	−46.00% (below 0%: shrinking)	n/m	−195.04% (below 0%: shrinking)	43.33%	(3,194.81%)	Compare
ALLR Allarity Therapeutics, Inc.	$13.2M	— (loss-making)	— (loss-making)	—	n/m	+53.22% (above 0%: growing)	100.00%	0.00%	Compare
CTXR Citius Pharmaceuticals, Inc.	$12.6M	— (loss-making)	—	—	n/m	−60.50% (below 0%: shrinking)	67.07%	(785.39%)
CASIF CASI Pharmaceuticals Inc.	$12.4M	— (loss-making)	— (loss-making)	−45.93% (below 0%: shrinking)	n/m	−23,251.69% (below 0%: shrinking)	51.14%	(147.67%)	Compare
AEON AEON Biopharma, Inc.	$12.1M	— (loss-making)	—	—	n/m	−76.85% (below 0%: shrinking)	—	0.00%	Compare
ASBP Aspire-Lakewood Holdings, Inc.	$12.1M	0.2×	—	—	n/m	−85.54% (below 0%: shrinking)	(47.70%)	(4,244.37%)	Compare
ACTU Actuate Therapeutics, Inc.	$12.0M	— (loss-making)	—	—	n/m	−5.54% (below 0%: shrinking)	—	0.00%	Compare
PLUR Pluri Inc.	$11.9M	— (loss-making)	— (loss-making)	−15.83% (below 0%: shrinking)	n/m	+25.03% (above 0%: growing)	58.51%	(1,655.52%)	Compare
Median of peers	$12.3M	—	—	−30.88%	—	−41.19%	54.82%	(382.04%)

All 614 Biotechnology stocks →

Citius Pharmaceuticals, Inc. (CTXR) key facts

Citius Pharmaceuticals, Inc. (CTXR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CTXR traded at $0.46, a market capitalization of $12.6 million.
Return on equity was −49.4% and debt-to-equity 0.08.

Source: company filings (standardised) and stockrow calculations.